<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?</h2>
    <div class="badge">2025-09-15T14:27:00+00:00</div>
    <ul>
      <li>Shares of CorMedix CRMD have soared 59.7% in the year-to-date period.</li>
<li>In the past year, CorMedix shares have surged 83.3% against the industry’s 13.8% decline.</li>
<li>In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues.</li>
<li>In the first half of 2025, DefenCath delivered $78.8 million in net revenues, reflecting a solid start to its commercial journey.</li>
<li>CorMedix has also raised its guidance for DefenCath sales to the range of $200-$215 million in 2025 compared with the previous expectation of $180-$200 million in sales.</li>
<li>market exclusivity through 2033.</li>
<li>Management now expects 2025 pro forma revenues in the $325-$350 million range, with the deal projected to be accretive to earnings per share by 2026.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=CorMedix%20Rallies%2060%25%20YTD%3A%20Is%20This%20an%20Indication%20to%20Buy%20the%20Stock%3F%0A%E2%80%A2%20Shares%20of%20CorMedix%20CRMD%20have%20soared%2059.7%25%20in%20the%20year-to-date%20period.%0A%E2%80%A2%20In%20the%20past%20year%2C%20CorMedix%20shares%20have%20surged%2083.3%25%20against%20the%20industry%E2%80%99s%2013.8%25%20decline.%0A%E2%80%A2%20In%202025%2C%20CorMedix%20anticipates%20Melinta%E2%80%99s%20portfolio%20to%20generate%20%24125%20million%20to%20%24135%20million%20in%20revenues.%0A%E2%80%A2%20In%20the%20first%20half%20of%202025%2C%20DefenCath%20delivered%20%2478.8%20million%20in%20net%20revenues%2C%20reflecting%20a%20solid%20start%20to%20its%20commercial%20journey.%0A%E2%80%A2%20CorMedix%20has%20also%20raised%20its%20guidance%20for%20DefenCath%20sales%20to%20the%20range%20of%20%24200-%24215%20million%20in%202025%20compared%20with%20the%20previous%20expectation%20of%20%24180-%24200%20million%20in%20sales.%0A%E2%80%A2%20market%20exclusivity%20through%202033.%0A%E2%80%A2%20Management%20now%20expects%202025%20pro%20forma%20revenues%20in%20the%20%24325-%24350%20million%20range%2C%20with%20the%20deal%20projected%20to%20be%20accretive%20to%20earnings%20per%20share%20by%202026.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fcormedix-rallies-60-ytd-is-this-an-indication-to-buy-the-stock%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/cormedix-rallies-60-ytd-indication-142700729.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>